Please join Rancho’s upcoming Pistoia Alliance webinar UNPACKING UNSTRUCTURED DATA:
EXTRACTING INSIGHTS FROM NEUROPATHOLOGICAL REPORTS OF PARKINSON’S DISEASE PATIENTS USING LARGE LANGUAGE MODELS.
Date: November 8, 2023 Time: 8:00 am PT
Harmonizing disease phenotypes to support genetic analysis:
Please join Rancho’s joint webinar with Takeda on Harmonizing Disease Phenotypes to Support Genetic Analysis.
Date: October 11, 2023 Time: 10:00 am PT / 1:00 pm ET
Register Here: https://lnkd.in/egZH2BJW
Rancho was proud to participate in the Crohn's & Colitis Take Steps walk in June. Not only was this for a great cause, we also had a great time!
28 Rancher’s Raised: $6,093
Rancho Donated: $5,000
Total Donated: $11,093
• Top 3 Raisers: Maryann Whitley, Kevin Blighe, Joseph Ramirez
• Ranchers that raised $150 or more: Maryann Whitley, Kevin Blighe, Joseph Ramirez, Jon Greene, Julie Bryant, Cindy Grondin
Rancho will be attending The Festival of Genomics & Biodata Boston October 4 – 5, 2023. We hope to see you there!
Rancho is thrilled to be going to Basel, Switzerland to attend the BioTechX Europe conference October 4th – 6th, 2023.
Please come visit Rancho in Boston November 14 – 15, 2023 at the Pistoia Alliance Conference.
Julie Bryant has been recognized as one of The Top 50 Women Leaders of San Diego for 2022.
Julie Bryant is Chief Executive Officer and Founder of Rancho BioSciences, on a mission to save lives through data. Rancho BioSciences is an international fee for service data curation company with analysis and developer services. Their customers include pharma, foundations, government, and biotech companies. Rancho BioSciences is celebrating its 10-year anniversary and is experiencing exponential growth. Their strong culture code attracts the best scientists and developers that want to make a difference.
Over the years Bryant has built strong teams in GeneGo and later sold to Thomson Reuters. She was also involved in the acquisition of FreedomVoice by GoDaddy. She is on the advisory board of Rady Children's Hospital and the Brain Trust Committee at John Wayne Cancer Institute. Bryant is a graduate of Coventry University.
Quantitation of CD137 and Nectin-4 expression across multiple tumor types to support indication selection for BT7480, a Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™)
David Galbraith and Dan Rozelle supported exciting new work with Bicycle Therapeutic which was presented at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting. BT7480 is a Bicycle TICA™ (synthetic peptides with antibody-like affinities) that binds both CD137 on immune cells and Nectin-4 on cancer cells to deliver a potent anti-tumor immune signal in Nectin-4 expressing tumors. David's work on this project established an analysis framework of bulk tumor transcriptomic data integrated with multiplexed tumor immunofluorescence data to support prioritization of indications for BT7480 clinical development based on colocalization of both targets.
Building towards a computational infrastructure to aid in the interpretation of Bicycle® toxin conjugate response profiles.
As part of the BioITWorld Conference in September 2021, Bicycle Therapeutics presented work that was supported by Rancho Bioinformatics Scientists: David Galbraith and Dan Rozelle. As part of this project Rancho leveraged public transcriptomic data to identify genes associated with sensitivity to microtubule binding agents (MTBA) across various therapeutic indications in oncology.
Molecular-based enrichment strategy for Nectin-4 targeted Bicycle toxin conjugate BT8009.
Work with Bicycle Therapeutics supported by Dan Rozelle was presented at the American Association for Cancer Research (AACR) in April 2021. This poster described a clinical subject enrichment strategy based on Nectin-4 molecular profiling. This has enabled Bicycle to leverage existing profiling technologies to identify tumors that highly express their target of interest.
Differentiation of Azacitidine vs Oral AZA: Oral AZA results in a sustained hypomethylation and targets leukemic stem cells.
Congratulations to Nathalie Lailler and Chris Hartl for being named on an abstract that has been accepted for poster presentation at the American Society for Hematology meeting in December.
Implementation of the FAIR Data Principles for Exploratory Biomarker Data from Clinical Trials.
Alexander Arefolov, Laura Adam, Shoshana Brown, Yelena Budovskaya, Cong Chen, Diya Das, Chen Farhy, Rebecca Ferguson, Hongmei Huang, Kimberly Kanigel, Christina Lu, Oksana Polesskaya, Tracy Staton, Rajeev Tajhya, Maryann Whitley, Jee-Yeon Wong, Xiangpei Zeng & Mark McCreary, Data Intelligence 2021,3(4):631–662.
The CHDI/Rancho publication is available as preprint
This publication is the culmination of many years of work by Rancho curators, bioinformaticians, and developers. The Rancho team helped develop the HDinHD Explorer tool that brings together a variety of experimental data related to Huntington disease (HD) research. In addition, Rancho was responsible for creating content for the tool by curating experimental information from thousands of publications and internal CHDI reports, as well as analyzing hundreds of public datasets.
HDinHD (Huntington's Disease in High Definition; HDinHD.org) is an open online portal for the HD research community that presents a synthesized view of HD-related scientific data. Here, we present a broad overview of HDinHD and highlight the newly launched HDinHD Explorer tool that enables researchers to discover and explore a wide range of diverse yet interconnected HD-related data. We demonstrate the utility of HDinHD Explorer through data mining of a single collection of newly released in vivo therapeutic intervention study reports alongside previously published reports.
Viktoria Andreeva, Irina Murasheva, Anastasia Shneyderman, Kabenla Armah, Rob Gill
Rancho provides funds for a pilot project to fast-track the development of affordable cancer treatments.
Cancer patients don’t have the time to wait for new drugs to be developed. Reboot Rx is the tech nonprofit startup dedicated to saving the lives of cancer patients using existing non-cancer generic drugs. In their Prostate Cancer Project, which was inspired by a patient advocate, Reboot Rx is: 1) using their AI technology to rapidly identify clinical publications where non-cancer generics have been tested for the treatment of prostate cancer from over 15,000 studies, 2) extracting key information from each study, including whether the drug was found to be effective for prostate cancer, and 3) aggregating the evidence into a user-friendly dashboard to share with prostate cancer doctors and patients to inform which generic drugs should be prioritized for Phase II/III clinical trials.
CDK is an open source Cheminformatics Java Library that has been under development for over 20 years. Recently, CDK released version 2.5, which includes several bug fixes. The CDK library is widely used in the FDA G-SRS project, and it assists agencies in registering and documenting information about substances found in medicines. Since many institutes around the world prefer to use open source software, G-SRS uses CDK in its default configuration.
The AMP-PD program, which is managed through FNIH, aims to identify and validate the most promising biological targets for therapeutics. AMP-PD has listed Alena Fedarovich and Leonya Ivanov from Rancho BioSciences on their websites showing how we/they utilized our Smart Converter tool - a set of Python and Java based custom scripts to perform data curation and update & format studies for loading into the AMP PD Knowledge Portal.
NIH’s Moonshot Project To Globally Register Medicinal Ingredients
January 31, 2020 | What’s in a name? When it comes to ingredients found in medicine, quite a lot of important detail. That’s why NIH’s NCATS (National Center for Advancing Translational Sciences) has been working to marshal a definitive resource for medicinal ingredients.